Experiences from the Institute for Neuropathic pain with palmitoylethanolamoide in patients suffering from chronic pain

Palmitoylethanolamide is a recent addition in the area of pain treatment, without negative side effects.  In July 2012, professor Sabato’s anesthesiologist group of the university of Rome published an overview of the effectiveness of palmitoylethanolamide on over 600 patients, all of which experienced unmanageable pain.

Once again, the results were impressive. No side effects were mentioned and the pain relief worked on a variety of pain problems.

In the words of the researchers themselves:

  1. PEA treatment significantly decreased the mean score pain intensity evaluated in all patients who completed the study.
  2. The PEA effect was independent of the pain associated pathological condition.
  3. PEA-induced decrease of pain intensity was present also in patients without concomitant analgesic therapy.
  4. Importantly, PEA showed no adverse effects.

The conclusion was:

In this study, PEA was effective and safe in the management of chronic pain in different pathological conditions. [1]

Since 2010 a lot of patients have been treated with PEA in the Netherlands, also for various sorts of pain. Here are the results of a Dutch evaluation of patients reporting their own results:

This year (2012), between January and July, 75 patients spontaneously reported their experiences. Here are the results:


Patient experiences on the use of palmitoylethanolamide

Condition: Number of patients: Average result:
Vaginal pain complaints 6 + to ++ (good to very good
Neuropathic pains 44 + (good)
Hernia/back pain 4 ++ (very good)
Joint pain / rheumatoid arthritis 9 + (good)
Phantom pain 1 ++ (very good)
Spasms 1 ++ (very good)
Tremors 1 – (no effect)
Facial pain 1 + (good)
MS 1 ++ (very good)
Shingles 2 ++ (very good)
Bladder pain 2 + (good)
Eczema 1 – (no effect)
Irritable Bowel Syndrome 1 ++ (very good)
Jaw pain 1 – (no effect)
Total 75 + to ++ (good to very good)


No negative side effects were reported in 2012, with the exception of the Normast tablet being a little heavy to digest in rare cases. There were 2 cases of loose stool or diarrhea after taking Normast powder, which was explained by the addition of Sorbitol as a sweetener. Luckily, since 2012, a pure form of PEA has been available without any chemical additives, called PeaCure.

A few patients found the tablets a little challenging to swallow.

No negative interactions with other medicine were reported.

In summary it looks like the natural pain reliever PEA is very easy to tolerate and has a good contribution towards pain relief for the majority of patients of which the indications vary from neuropathic pains (diabetes, CIAP) to phantom pains.

Rapport on the effects of palmitoylethanolamide on patients during the second half of 2011

It is interesting to show the results of spontaneous reports in the second half of 2011 in a similar way:

Condition: Number of patients: Average result:
Vaginal pain complaints 5 + to ++ (good to very good
Neuropathic pains 46 + (good)
Hernia/back pain 5 + (good)
Joint pain / arthritis 8 + (good)
Rheumatoid Arthritis 6 ++ (very good)
Migraine 1 + (good)
Small fiber neuropathic pain 1 ++ (very good)
Frozen shoulder 2 + (good)
MS 1 ++ (very good)
Shingles 3 + (good)
Bladder pain 2 + (good)
Hip tendon inflammation 1 – (no effect)
Gastroenteritis 1 ++ (very good)
Neuralgia 1 + (good)
IC 1 – (no effect)
Fibromyalgia 1 + (good)
Total 85 + to ++ (good to very good)

As a response to our appeal in the second half of 2011, a total of 85 patients reported with their experience. We can see a similar picture here, a good to very good response with palmitoylethanolamide and no relevant side effects.

We have received a total of 160 spontaneous rapports from patients in the period between July 2011 and July 2012, of which the majority clearly benefited from the treatment with palmitoylethanolamide.



[1] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. | Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. | Pain Med. | 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x. Epub 2012 Jul 30.

%d bloggers like this: